Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells
- PMID: 20035613
- PMCID: PMC3196214
- DOI: 10.1089/adt.2009.0208
Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells
Abstract
Receptor tyrosine kinases (RTKs) in the ErbB family (EGFR, ErbB2, ErbB3, and ErbB4) are implicated in a variety of human malignancies. Accordingly, determination of both expression and activation (dimerization/heterodimerization and phosphorylation) of ErbB proteins is critical in defining their functional role in cancer. Efficient and comprehensive methods to study molecular functions of ErbB family of RTKs are needed not only for improvements in diagnostics but also for early screening of targeted drugs (eg, small molecule inhibitors and therapeutic antibodies). We report development of 3 multiplex microbead immunoassays for simultaneous detection of expression, protein-protein interactions, and phosphorylation of these RTKs. These novel multiplex immunoassays were used to study ErbB RTKs under different cell activation conditions in 2 breast cancer cell lines (MDA-MB-453 and MDA-MB-468) and an epidermoid cancer cell line (A431). The results were confirmed by immunoprecipitation/western blot. Importantly, the multiplex immunoassay facilitated time-course studies in these cell lines after cell activation with EGF and neuregulin, revealing the kinetics of phosphorylation of the ErbB family RTKs. This study demonstrates the utility of the Luminex(R) multiplex system as an efficient and comprehensive approach to study different aspects of molecular roles of these RTKs. Importantly, the study provides proof-of-concept for the utility of the multiplex microbead immunoassay approach for potential use in efficient, robust, and rapid screening of drugs, particularly those targeting functional aspects of these potent signaling molecules. In addition, the assays described here may be useful for cancer diagnostics and monitoring efficacy of therapy targeting the ErbB family of RTKs.
Figures
Similar articles
-
Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.Cell Signal. 2007 Mar;19(3):466-71. doi: 10.1016/j.cellsig.2006.07.020. Epub 2006 Sep 15. Cell Signal. 2007. PMID: 16978839
-
Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.Cytometry. 2001 Aug 1;44(4):338-48. doi: 10.1002/1097-0320(20010801)44:4<338::aid-cyto1125>3.0.co;2-v. Cytometry. 2001. PMID: 11500850
-
ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.Cancer Med. 2012 Aug;1(1):28-38. doi: 10.1002/cam4.10. Epub 2012 Jul 15. Cancer Med. 2012. PMID: 23342251 Free PMC article.
-
ErbB Receptors and Cancer.Methods Mol Biol. 2017;1652:3-35. doi: 10.1007/978-1-4939-7219-7_1. Methods Mol Biol. 2017. PMID: 28791631 Review.
-
The ErbB/HER family of protein-tyrosine kinases and cancer.Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Pharmacol Res. 2014. PMID: 24269963 Review.
Cited by
-
No evidence for xenotropic murine leukemia-related virus infection in Sweden using internally controlled multiepitope suspension array serology.Clin Vaccine Immunol. 2012 Sep;19(9):1399-410. doi: 10.1128/CVI.00391-12. Epub 2012 Jul 11. Clin Vaccine Immunol. 2012. PMID: 22787191 Free PMC article.
-
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.Nat Rev Cancer. 2010 Sep;10(9):618-29. doi: 10.1038/nrc2900. Epub 2010 Aug 19. Nat Rev Cancer. 2010. PMID: 20720570 Review.
-
Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology.Sci Rep. 2019 Apr 2;9(1):5531. doi: 10.1038/s41598-019-41722-z. Sci Rep. 2019. PMID: 30940836 Free PMC article.
-
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.J Biol Chem. 2011 Apr 1;286(13):11337-45. doi: 10.1074/jbc.M111.223503. Epub 2011 Jan 31. J Biol Chem. 2011. PMID: 21282108 Free PMC article.
-
Betacellulin (BTC) Biases the EGFR To Dimerize with ErbB3.Mol Pharmacol. 2018 Dec;94(6):1382-1390. doi: 10.1124/mol.118.113399. Epub 2018 Sep 24. Mol Pharmacol. 2018. PMID: 30249613 Free PMC article.
References
-
- Lo HW. Hsu SC. Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat. 2006;95:211–218. - PubMed
-
- Ono M. Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006;12:7242–7251. - PubMed
-
- Sweeney C. Miller JK. Shattuck DL. Carraway KL. ErbB receptor negative regulatory mechanisms: implications in cancer. J Mammary Gland Biol Neoplasia. 2006;11:89–99. - PubMed
-
- Agrawal A. Gutteridge E. Gee JM. Nicholson RI. Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005;12(Suppl 1):S135–S144. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
